Toyoda M, Kakizaki S, Horiguchi N, Sato K, Takayama H, Takagi H, Nagamine T, Mori M
The First Department of Internal Medicine, Gunma University School of Medicine, Maebashi, Japan.
Liver. 2000 Jul;20(4):305-11. doi: 10.1034/j.1600-0676.2000.020004305.x.
AIMS/BACKGROUND: To determine the relationship between host factors and host response to interferon (IFN) therapy, serum soluble Fas (sFas), soluble Fas ligand (sFas ligand), and tumor necrosis factor-alpha (TNF-alpha) were analyzed in 41 patients with chronic hepatitis C (CH-C) treated with IFN-alpha.
Serum levels of sFas, sFas ligand, and TNF-alpha were measured at 0, 4, and 24 weeks of IFN therapy.
Eighteen patients were complete responders (CR) and 23 patients were non-responders (NR). Serum levels of sFas and TNF-alpha in patients with CHC were significantly higher than those in healthy controls (p<0.01 and p<0.01, respectively). Serum sFas ligand levels were significantly lower in CH-C patients than in healthy controls (p<0.01). Before IFN therapy, serum levels of sFas in NR were significantly higher than those in CR (p<0.05). At 4 weeks of IFN therapy, serum levels of sFas of CR were significantly elevated compared with levels before IFN therapy (p<0.05). Serum levels of sFas correlated with the histological activity of the liver (p<0.05) and alanine aminotransferase (p<0.05). None of the three parameters, serum sFas, sFas ligand, or TNF-alpha levels, correlated with each other, with HCV-RNA genotype or with serum HCV-RNA load. Multiple logistic regression analysis showed that serum sFas levels before IFN therapy were a contributive factor to predict efficacy of IFN therapy.
Serum sFas/sFas ligand and TNF-alpha play a possible role in pathogenesis of CH-C and also in IFN therapy. Serum sFas levels before IFN therapy may be one of the host-related factors used for evaluating the response of CH-C patients to IFN therapy.
目的/背景：为确定宿主因素与宿主对干扰素（IFN）治疗反应之间的关系，对41例接受α干扰素治疗的慢性丙型肝炎（CH-C）患者的血清可溶性Fas（sFas）、可溶性Fas配体（sFas配体）和肿瘤坏死因子-α（TNF-α）进行了分析。
在IFN治疗的0、4和24周时测量血清sFas、sFas配体和TNF-α水平。
18例患者为完全缓解者（CR），23例患者为无反应者（NR）。CHC患者的血清sFas和TNF-α水平显著高于健康对照者（分别为p<0.01和p<0.01）。CH-C患者的血清sFas配体水平显著低于健康对照者（p<0.01）。在IFN治疗前，NR患者的血清sFas水平显著高于CR患者（p<0.05）。在IFN治疗4周时，CR患者的血清sFas水平与IFN治疗前相比显著升高（p<0.05）。血清sFas水平与肝脏组织学活性（p<0.05）和丙氨酸转氨酶（p<0.05）相关。血清sFas、sFas配体或TNF-α水平这三个参数之间均无相关性，与HCV-RNA基因型或血清HCV-RNA载量也无相关性。多因素logistic回归分析显示，IFN治疗前的血清sFas水平是预测IFN治疗疗效的一个因素。
血清sFas/sFas配体和TNF-α可能在CH-C的发病机制以及IFN治疗中发挥作用。IFN治疗前的血清sFas水平可能是用于评估CH-C患者对IFN治疗反应的宿主相关因素之一。
